{"id":449,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"modified":"2026-08-28T07:42:46","modified_gmt":"2026-08-28T07:42:46","slug":"retatrutide-triple-agonist-phase-2-evidence","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/retatrutide-triple-agonist-phase-2-evidence\/","title":{"rendered":"\u0627\u0644\u0646\u0627\u0647\u0636\u0629 \u0627\u0644\u062b\u0644\u0627\u062b\u064a\u0629 \u0644\u0631\u064a\u062a\u0627\u062a\u0631\u0648\u062a\u0627\u064a\u062f: \u0645\u0627 \u0648\u062c\u062f\u062a\u0647 \u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0648\u0645\u0627 \u0644\u0645 \u064a\u062b\u0628\u062a\u0647"},"content":{"rendered":"

\u062a\u0645 \u062a\u0635\u0645\u064a\u0645 Retatrutide \u0644\u062a\u0646\u0634\u064a\u0637 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a GIP \u0648GLP-1 \u0648\u0627\u0644\u062c\u0644\u0648\u0643\u0627\u062c\u0648\u0646 \u0641\u064a \u062c\u0632\u064a\u0621 \u0648\u0627\u062d\u062f. \u0648\u0642\u062f \u0623\u062b\u0627\u0631\u062a \u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0645\u0646\u0629 2023 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0645\u0631\u062d\u0644\u0629 2 \u0627\u0647\u062a\u0645\u0627\u0645\u064b\u0627 \u0643\u0628\u064a\u0631\u064b\u0627\u060c \u0644\u0643\u0646 \u0627\u0644\u062a\u0641\u0633\u064a\u0631 \u0627\u0644\u0635\u062d\u064a\u062d \u064a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062a\u062c\u0631\u0628\u0629\u060c \u0648\u0627\u0644\u0633\u0643\u0627\u0646\u060c \u0648\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629\u060c \u0648\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0623\u062d\u062f\u0627\u062b \u0627\u0644\u0633\u0644\u0628\u064a\u0629\u060c \u0648\u0645\u0627 \u0628\u0642\u064a \u063a\u064a\u0631 \u0645\u0639\u0631\u0648\u0641.<\/p>

\u0627\u0644\u0648\u062c\u0628\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629<\/h2>
  • Retatrutide \u0647\u0648 \u062c\u0632\u064a\u0621 \u0627\u0633\u062a\u0642\u0635\u0627\u0626\u064a \u0648\u0627\u062d\u062f \u0644\u0647 \u0646\u0634\u0627\u0637 \u0641\u064a \u062b\u0644\u0627\u062b\u0629 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0647\u0631\u0645\u0648\u0646\u064a\u0629.<\/li>
  • \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0645\u0642\u062a\u0628\u0633\u0629 \u0628\u0634\u0643\u0644 \u0645\u062a\u0643\u0631\u0631 \u062a\u0623\u062a\u064a \u0645\u0646 \u062a\u062c\u0631\u0628\u0629 338 \u0644\u0645\u0631\u062d\u0644\u0629 2\u060c \u0648\u0644\u064a\u0633 \u0642\u0631\u0627\u0631 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629.<\/li>
  • \u0644\u0627 \u064a\u0639\u0646\u064a \u0625\u0643\u0645\u0627\u0644 \u0645\u0631\u062d\u0644\u0629 \u062f\u0631\u0627\u0633\u0629 3 \u0641\u064a \u062d\u062f \u0630\u0627\u062a\u0647 \u0646\u0634\u0631 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0623\u0648 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u0649 \u0627\u0644\u0645\u0646\u062a\u062c.<\/li><\/ul><\/div><\/div>
    \"\u0628\u0627\u062d\u062b
    \u0631\u0633\u0645 \u062a\u0648\u0636\u064a\u062d\u064a \u062a\u062d\u0631\u064a\u0631\u064a \u0623\u0635\u0644\u064a \u0644\u062b\u0644\u0627\u062b\u0629 \u0645\u0633\u0627\u0631\u0627\u062a \u0644\u0625\u0634\u0627\u0631\u0629 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0641\u064a \u0645\u062e\u062a\u0628\u0631 \u0627\u0644\u0623\u0628\u062d\u0627\u062b\u061b \u0644\u064a\u0633 \u062a\u0635\u0648\u064a\u0631\u0627 \u0644\u0644\u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629.<\/figcaption><\/figure>

    \u0645\u0641\u0647\u0648\u0645 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u062b\u0644\u0627\u062b\u0629<\/h2>

    Retatrutide\u060c \u0627\u0644\u0645\u0639\u0631\u0648\u0641 \u0623\u064a\u0636\u064b\u0627 \u0641\u064a \u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u0637\u0648\u064a\u0631 \u0628\u0627\u0633\u0645 LY3437943\u060c \u0647\u0648 \u0646\u0627\u0647\u0636 \u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a GIP \u0648GLP-1 \u0648\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u062c\u0644\u0648\u0643\u0627\u062c\u0648\u0646. \u0648\u0635\u0641\u0647 \u0628\u0623\u0646\u0647 \u0646\u0627\u0647\u0636 \u062b\u0644\u0627\u062b\u064a \u064a\u0635\u0641 \u0639\u0644\u0645 \u0627\u0644\u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u064a. \u0641\u0647\u0648 \u0644\u0627 \u064a\u062a\u0646\u0628\u0623 \u0641\u064a \u062d\u062f \u0630\u0627\u062a\u0647 \u0628\u062d\u062c\u0645 \u0627\u0644\u0646\u062a\u064a\u062c\u0629 \u0623\u0648 \u062f\u064a\u0645\u0648\u0645\u062a\u0647\u0627 \u0623\u0648 \u0633\u0644\u0627\u0645\u062a\u0647\u0627 \u0644\u062f\u0649 \u0645\u062c\u0645\u0648\u0639\u0629 \u0633\u0643\u0627\u0646\u064a\u0629 \u0645\u0639\u064a\u0646\u0629.<\/p>

    \u0648\u064a\u0633\u0627\u0647\u0645 \u062a\u0648\u0627\u0632\u0646 \u0627\u0644\u0646\u0634\u0627\u0637 \u0639\u0628\u0631 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u062b\u0644\u0627\u062b\u0629\u060c \u0648\u0645\u0644\u0641 \u062a\u0639\u0631\u0636 \u0627\u0644\u062c\u0632\u064a\u0621\u060c \u0648\u0627\u0644\u062a\u0631\u0643\u064a\u0628\u0629 \u0627\u0644\u0645\u062f\u0631\u0648\u0633\u0629\u060c \u0641\u064a \u0627\u0644\u062a\u0623\u062b\u064a\u0631\u0627\u062a \u0627\u0644\u0645\u0644\u062d\u0648\u0638\u0629.<\/p>

    \u0645\u0627 \u062a\u0645 \u0642\u064a\u0627\u0633\u0647 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 2<\/h2>

    \u0633\u062c\u0644\u062a \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629 \u0627\u0644\u062a\u064a \u062a\u0645 \u0627\u0644\u062a\u062d\u0643\u0645 \u0641\u064a\u0647\u0627 \u0628\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0648\u0647\u0645\u064a 338 \u0627\u0644\u0628\u0627\u0644\u063a\u064a\u0646 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0627\u0644\u0633\u0645\u0646\u0629 \u0623\u0648 \u0632\u064a\u0627\u062f\u0629 \u0627\u0644\u0648\u0632\u0646 \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062d\u0627\u0644\u0629 \u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u0648\u0632\u0646. \u0648\u0643\u0627\u0646\u062a \u0646\u0642\u0637\u0629 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0627\u0644\u0646\u0633\u0628\u0629 \u0627\u0644\u0645\u0626\u0648\u064a\u0629 \u0644\u0644\u062a\u063a\u064a\u0631 \u0641\u064a \u0648\u0632\u0646 \u0627\u0644\u062c\u0633\u0645 \u0641\u064a \u0623\u0633\u0627\u0628\u064a\u0639 24\u061b \u0643\u0627\u0646 \u0627\u0644\u062a\u063a\u064a\u064a\u0631 \u0644\u0645\u062f\u0629 \u0623\u0633\u0628\u0648\u0639 48 \u0648\u0639\u062a\u0628\u0627\u062a \u062e\u0641\u0636 \u0627\u0644\u0648\u0632\u0646 \u0627\u0644\u0641\u0626\u0648\u064a\u0629 \u0647\u064a \u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u062b\u0627\u0646\u0648\u064a\u0629. \u0643\u0627\u0646\u062a \u0627\u0644\u0623\u062d\u062f\u0627\u062b \u0627\u0644\u0645\u0639\u062f\u064a\u0629 \u0627\u0644\u0645\u0639\u0648\u064a\u0629 \u0647\u064a \u0627\u0644\u0623\u062d\u062f\u0627\u062b \u0627\u0644\u0636\u0627\u0626\u0631\u0629 \u0627\u0644\u0623\u0643\u062b\u0631 \u0634\u064a\u0648\u0639\u064b\u0627\u060c \u0648\u0642\u062f \u0644\u0648\u062d\u0638\u062a \u0632\u064a\u0627\u062f\u0627\u062a \u0641\u064a \u0645\u0639\u062f\u0644 \u0636\u0631\u0628\u0627\u062a \u0627\u0644\u0642\u0644\u0628 \u062a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u062c\u0631\u0639\u0629 \u0642\u0628\u0644 \u0623\u0646 \u062a\u0646\u062e\u0641\u0636 \u0644\u0627\u062d\u0642\u064b\u0627 \u0641\u064a \u0627\u0644\u062f\u0631\u0627\u0633\u0629.<\/p>

    \u0623\u0646\u0634\u0623\u062a \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0625\u0634\u0627\u0631\u0629 \u0627\u0644\u0627\u0633\u062a\u062c\u0627\u0628\u0629 \u0644\u0644\u062c\u0631\u0639\u0629 \u0648\u062f\u0639\u0645\u062a \u062a\u0637\u0648\u064a\u0631 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 3. \u0648\u0644\u0645 \u062a\u062d\u062f\u062f \u0641\u0648\u0627\u0626\u062f \u0648\u0645\u062e\u0627\u0637\u0631 \u0637\u0648\u064a\u0644\u0629 \u0627\u0644\u0623\u062c\u0644 \u0639\u0628\u0631 \u0645\u062c\u0645\u0648\u0639\u0627\u062a \u0623\u0648\u0633\u0639 \u0645\u0646 \u0627\u0644\u0633\u0643\u0627\u0646\u060c \u0623\u0648 \u0627\u0644\u062a\u0641\u0648\u0642 \u0627\u0644\u0645\u0628\u0627\u0634\u0631 \u0639\u0644\u0649 \u0643\u0644 \u0628\u062f\u064a\u0644\u060c \u0623\u0648 \u0627\u0644\u062a\u0643\u0627\u0641\u0624 \u0628\u064a\u0646 \u0627\u0644\u0645\u0648\u0627\u062f \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629 \u0648\u0645\u0646\u062a\u062c \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c.<\/p>

    \u062a\u0635\u0645\u064a\u0645<\/strong>\u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0647\u0645\u064a \u062a\u0633\u064a\u0637\u0631 \u0639\u0644\u064a\u0647\u0627 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 2 \u0627\u0644\u0645\u062d\u0627\u0643\u0645\u0629<\/span><\/div>
    \u0645\u0634\u0627\u0631\u0643\u0648\u0646<\/strong>\u0627\u0644\u0643\u0628\u0627\u0631 338<\/span><\/div>
    \u0645\u062f\u0629<\/strong>\u0623\u0633\u0627\u0628\u064a\u0639 48<\/span><\/div>
    \u0627\u0644\u062d\u062f\u0648\u062f \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629<\/strong>\u0623\u062f\u0644\u0629 \u062a\u062d\u0642\u064a\u0642\u064a\u0629\u060c \u0648\u0644\u064a\u0633\u062a \u0645\u0648\u0627\u0641\u0642\u0629 FDA<\/span><\/div><\/div><\/div>

    \u0645\u0627 \u0627\u0644\u0630\u064a \u062a\u063a\u064a\u0631 \u0628\u0648\u0627\u0633\u0637\u0629 2026<\/h2>

    \u064a\u062f\u0631\u062c \u0645\u0648\u0642\u0639 ClinicalTrials.gov TRIUMPH-1 \u0643\u0645\u0631\u062d\u0644\u0629 \u0645\u0643\u062a\u0645\u0644\u0629 \u0644\u062f\u0631\u0627\u0633\u0629 3\u060c \u0645\u0639 \u0627\u0643\u062a\u0645\u0627\u0644 \u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0641\u064a \u0623\u0628\u0631\u064a\u0644 2026 \u0648\u0644\u0645 \u064a\u062a\u0645 \u0646\u0634\u0631 \u0623\u064a \u0646\u062a\u0627\u0626\u062c \u0641\u064a \u0627\u0644\u0633\u062c\u0644 \u0627\u0644\u0630\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647 \u0644\u0647\u0630\u0647 \u0627\u0644\u0645\u0642\u0627\u0644\u0629. \"\u0645\u0643\u062a\u0645\u0644\" \u064a\u0635\u0641 \u062d\u0627\u0644\u0629 \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u061b \u0648\u0644\u0627 \u064a\u062d\u0644 \u0645\u062d\u0644 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0623\u0648 \u0645\u0631\u0627\u062c\u0639\u0629 \u0627\u0644\u0646\u0638\u0631\u0627\u0621 \u0623\u0648 \u0627\u0644\u062a\u0642\u064a\u064a\u0645 \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a.<\/p>

    \u062a\u0646\u0635 \u0627\u0644\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0627\u0644\u0639\u0627\u0645\u0629 \u0627\u0644\u062d\u0627\u0644\u064a\u0629 \u0644\u0640 FDA \u0639\u0644\u0649 \u0623\u0646 \u0627\u0644\u0631\u064a\u062a\u0627\u062a\u0631\u0648\u062a\u0627\u064a\u062f \u0644\u064a\u0633 \u0623\u062d\u062f \u0645\u0643\u0648\u0646\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA. \u0644\u0630\u0644\u0643 \u064a\u062c\u0628 \u0623\u0646 \u062a\u0635\u0641\u0647\u0627 \u0645\u0642\u0627\u0644\u0629 2026 \u0627\u0644\u062f\u0642\u064a\u0642\u0629 \u0628\u0623\u0646\u0647\u0627 \u062a\u062d\u0642\u064a\u0642\u064a\u0629 \u0645\u0627 \u0644\u0645 \u064a\u0646\u0635 \u0633\u062c\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0627\u0644\u0631\u0633\u0645\u064a \u0639\u0644\u0649 \u062e\u0644\u0627\u0641 \u0630\u0644\u0643.<\/p>

    2026 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062a\u064a \u0623\u0628\u0644\u063a \u0639\u0646\u0647\u0627 \u0627\u0644\u0631\u0627\u0639\u064a 3 \u0627\u0644\u062e\u0637 \u0627\u0644\u0639\u0644\u0648\u064a<\/h2>

    \u0623\u0628\u0644\u063a\u062a \u0634\u0631\u0643\u0629 Lilly \u0639\u0646 \u0646\u062a\u0627\u0626\u062c \u0631\u0626\u064a\u0633\u064a\u0629 \u0644\u0640 TRIUMPH-1 \u0641\u064a \u0645\u0627\u064a\u0648 21\u060c 2026: \u0641\u064a \u0623\u0633\u0627\u0628\u064a\u0639 80\u060c \u0623\u0628\u0644\u063a \u0627\u0644\u0631\u0627\u0639\u064a \u0639\u0646 \u0645\u062a\u0648\u0633\u0637 \u200b\u200b\u062a\u063a\u064a\u0631 \u0641\u064a \u0627\u0644\u0648\u0632\u0646 \u0642\u062f\u0631\u0647 \u221228.3% \u0644\u0645\u062c\u0645\u0648\u0639\u0629 12 mg. \u0641\u064a \u064a\u0648\u0644\u064a\u0648\u060c \u0623\u0628\u0644\u063a\u062a 23\u060c 2026\u060c Lilly \u0639\u0646 \u062a\u063a\u064a\u064a\u0631\u0627\u062a \u0645\u062a\u0648\u0633\u0637\u0629 \u062a\u0635\u0644 \u0625\u0644\u0649 \u221220.8% \u0641\u064a TRIUMPH-2 \u0648-22.6% \u0641\u064a TRIUMPH-3. \u0647\u0630\u0647 \u0647\u064a \u0625\u0641\u0635\u0627\u062d\u0627\u062a \u0627\u0644\u0631\u0627\u0639\u064a \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u060c \u0648\u0644\u064a\u0633\u062a \u0648\u062d\u062f\u0627\u062a \u0646\u062a\u0627\u0626\u062c ClinicalTrials.gov \u0623\u0648 \u0627\u0644\u062a\u0642\u0627\u0631\u064a\u0631 \u0627\u0644\u0643\u0627\u0645\u0644\u0629 \u0627\u0644\u062a\u064a \u0631\u0627\u062c\u0639\u0647\u0627 \u0627\u0644\u0646\u0638\u0631\u0627\u0621\u061b \u0644\u0627 \u062a\u0632\u0627\u0644 \u0627\u0644\u0623\u0633\u0627\u0644\u064a\u0628 \u0627\u0644\u062a\u0641\u0635\u064a\u0644\u064a\u0629 \u0648\u0642\u0631\u0627\u0631\u0627\u062a \u0627\u0644\u062a\u062d\u0644\u064a\u0644 \u0648\u062c\u062f\u0627\u0648\u0644 \u0627\u0644\u0623\u062d\u062f\u0627\u062b \u0627\u0644\u0633\u0644\u0628\u064a\u0629 \u0627\u0644\u0643\u0627\u0645\u0644\u0629 \u062a\u062a\u0637\u0644\u0628 \u0627\u0644\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u0643\u0627\u0645\u0644\u0629 \u0627\u0644\u0646\u0647\u0627\u0626\u064a\u0629. \u0648\u0627\u0635\u0644 \u0645\u0648\u0642\u0639 ClinicalTrials.gov \u0639\u0631\u0636 \"\u0644\u0645 \u064a\u062a\u0645 \u0646\u0634\u0631 \u0623\u064a \u0646\u062a\u0627\u0626\u062c\" \u0644\u0640 TRIUMPH-1 \u0641\u064a \u0647\u0630\u0647 \u0627\u0644\u0645\u0631\u0627\u062c\u0639\u0629.<\/p>","protected":false},"excerpt":{"rendered":"

    \u0642\u0631\u0627\u0621\u0629 \u0642\u0631\u064a\u0628\u0629 \u0644\u0635\u064a\u062f\u0644\u0629 GIP \u0648GLP-1 \u0648\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u062c\u0644\u0648\u0643\u0627\u062c\u0648\u0646 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0640 retatrutide \u0648\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0645\u0646\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0645\u062f\u0629 48 \u0623\u0633\u0628\u0648\u0639\u064b\u0627\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u0642\u064a\u0648\u062f \u0648\u062d\u0627\u0644\u0629 \u0627\u0644\u062a\u062d\u0642\u064a\u0642 \u0627\u0644\u062d\u0627\u0644\u064a\u0629.<\/p>","protected":false},"author":1,"featured_media":619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"359","pim_article_type":"Clinical trial evidence review","pim_evidence_level":"Randomized phase 2 human trial; investigational status","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 phase 2 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\",\"note\":\"Primary randomized phase 2 record; PMID 37366315.\"},{\"title\":\"TRIUMPH-1 phase 3 study record\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT05929066\",\"note\":\"ClinicalTrials.gov record updated June 2026; results not posted in the reviewed record.\"},{\"title\":\"FDA information on unapproved GLP-1 products\",\"url\":\"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss\",\"note\":\"Current regulatory-status boundary.\"},{\"title\":\"TRIUMPH-1 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss\",\"note\":\"Lilly primary-sponsor news release, May 21, 2026; not a peer-reviewed full report.\"},{\"title\":\"TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results\",\"url\":\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-triple-agonist-retatrutide-successful-two-additional\",\"note\":\"Lilly primary-sponsor news release, July 23, 2026; detailed results remain pending.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nRetatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD<\/title>\n<meta name=\"description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/ar\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\" \/>\n<meta property=\"og:description\" content=\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/ar\/retatrutide-triple-agonist-phase-2-evidence\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u062a\u0627\u0646\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\",\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:42:46+00:00\",\"description\":\"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/retatrutide-triple-agonist-phase-2-evidence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/ar\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Retatrutide \u0627\u0644\u0635\u0631\u0627\u0639 \u0627\u0644\u062b\u0644\u0627\u062b\u064a: \u0645\u0627 \u0648\u062c\u062f\u062a\u0647 \u0645\u0631\u062d\u0644\u0629 \u062a\u062c\u0631\u0628\u0629 2 - \u0648\u0644\u0645 \u064a\u062b\u0628\u062a - NHD","description":"\u0642\u0631\u0627\u0621\u0629 \u0642\u0631\u064a\u0628\u0629 \u0644\u0635\u064a\u062f\u0644\u0629 GIP \u0648GLP-1 \u0648\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u062c\u0644\u0648\u0643\u0627\u062c\u0648\u0646 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0640 retatrutide \u0648\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0645\u0646\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0645\u062f\u0629 48 \u0623\u0633\u0628\u0648\u0639\u064b\u0627\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u0642\u064a\u0648\u062f \u0648\u062d\u0627\u0644\u0629 \u0627\u0644\u062a\u062d\u0642\u064a\u0642 \u0627\u0644\u062d\u0627\u0644\u064a\u0629.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/ar\/retatrutide-triple-agonist-phase-2-evidence\/","og_locale":"ar_AR","og_type":"article","og_title":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","og_description":"A close reading of retatrutide\u2019s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current investigational status.","og_url":"https:\/\/nhdbio.com\/ar\/retatrutide-triple-agonist-phase-2-evidence\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:42:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"NHD Technical Team","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u062a\u0627\u0646"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"ar","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","url":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/","name":"Retatrutide \u0627\u0644\u0635\u0631\u0627\u0639 \u0627\u0644\u062b\u0644\u0627\u062b\u064a: \u0645\u0627 \u0648\u062c\u062f\u062a\u0647 \u0645\u0631\u062d\u0644\u0629 \u062a\u062c\u0631\u0628\u0629 2 - \u0648\u0644\u0645 \u064a\u062b\u0628\u062a - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:42:46+00:00","description":"\u0642\u0631\u0627\u0621\u0629 \u0642\u0631\u064a\u0628\u0629 \u0644\u0635\u064a\u062f\u0644\u0629 GIP \u0648GLP-1 \u0648\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u062c\u0644\u0648\u0643\u0627\u062c\u0648\u0646 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0640 retatrutide \u0648\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0645\u0646\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0644\u0645\u062f\u0629 48 \u0623\u0633\u0628\u0648\u0639\u064b\u0627\u060c \u0628\u0645\u0627 \u0641\u064a \u0630\u0644\u0643 \u0627\u0644\u0642\u064a\u0648\u062f \u0648\u062d\u0627\u0644\u0629 \u0627\u0644\u062a\u062d\u0642\u064a\u0642 \u0627\u0644\u062d\u0627\u0644\u064a\u0629.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/retatrutide-triple-agonist-phase-2-evidence-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/retatrutide-triple-agonist-phase-2-evidence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Retatrutide Triple Agonism: What the Phase 2 Trial Found\u2014and Did Not Prove"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u0645\u0648\u0627\u062f \u062e\u0627\u0645 \u0628\u0628\u062a\u064a\u062f\u064a\u0629 \u0648\u062a\u062e\u0644\u064a\u0642 \u0627\u0644\u0628\u0628\u062a\u064a\u062f\u0627\u062a \u062d\u0633\u0628 \u0627\u0644\u0637\u0644\u0628","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u0627\u0644\u0641\u0631\u064a\u0642 \u0627\u0644\u0641\u0646\u064a NHD","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"\u064a\u062d\u062a\u0641\u0638 \u0641\u0631\u064a\u0642 NHD \u0627\u0644\u0641\u0646\u064a \u0628\u0648\u062b\u0627\u0626\u0642 \u0643\u062a\u0627\u0644\u0648\u062c \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0628\u062d\u062b\u064a \u0648\u0645\u0644\u062e\u0635\u0627\u062a \u0627\u0644\u0623\u062f\u0644\u0629. \u062a\u0631\u062a\u0628\u0637 \u0627\u0644\u0645\u0642\u0627\u0644\u0627\u062a \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0628\u0627\u0644\u0623\u0648\u0631\u0627\u0642 \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0645\u0646 \u0642\u0628\u0644 \u0627\u0644\u0646\u0638\u0631\u0627\u0621\u060c \u0648\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0648\u0627\u0644\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629\u060c \u0648\u062a\u062d\u062a\u0641\u0638 \u0628\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0641\u0627\u0631\u063a\u0629 \u0648\u0642\u064a\u0648\u062f \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u060c \u0648\u062a\u0645\u064a\u0632 \u0627\u0644\u062a\u062f\u062e\u0644\u0627\u062a \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0629 \u0639\u0646 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c. \u064a\u0645\u0643\u0646 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0628\u0645\u0633\u0627\u0639\u062f\u0629 AI \u0644\u0644\u0647\u064a\u0643\u0644\u061b \u062a\u0638\u0644 \u0631\u0648\u0627\u0628\u0637 \u0627\u0644\u0645\u0635\u062f\u0631 \u0648\u062d\u062f\u0648\u062f \u0627\u0644\u0623\u062f\u0644\u0629 \u0645\u0631\u0626\u064a\u0629. \u0647\u0630\u0627 \u0627\u0644\u0639\u0645\u0644 \u0644\u064a\u0633 \u0645\u0631\u0627\u062c\u0639\u0629 \u0623\u0642\u0631\u0627\u0646 \u0645\u0633\u062a\u0642\u0644\u0629 \u0623\u0648 \u0646\u0635\u064a\u062d\u0629 \u0637\u0628\u064a\u0629.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/ar\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/comments?post=449"}],"version-history":[{"count":2,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/449\/revisions"}],"predecessor-version":[{"id":528,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/449\/revisions\/528"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media\/619"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media?parent=449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/categories?post=449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/tags?post=449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}